Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy
Vor Bio (VOR) has amended its existing collaboration agreement with RemeGen (REGMF) to include the development of RC298, a next-generation dual BAFF/APRIL inhibitor targeting autoimmune diseases. The expanded deal is valued at up to $356 million. Under the terms of this amendment, the Boston-based biotech will integrate the new therapeutic candidate into its research pipeline. This strategic move aims to leverage RemeGen's drug development capabilities to advance treatments for immune-mediated conditions.
Tickers: $VOR
Topics: Biotechnology Drug Development Strategic Partnership